Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936390 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,538
- Enrollment target
NCT00936390: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00936390 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,538 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936390, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,538 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Primary Outcome
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Five-year rates are provided here. Analysis was planned to occur after 218 deaths were reported.
Interventions
- DRUG bicalutamide
- DRUG flutamide
- RADIATION Dose-Escalated Radiation Therapy
- DRUG LHRH agonist (antagonist) therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,538 participants |
| Start Date | 2009-09 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
What the finished NCT00936390 record still lists
NCT00936390 is an interventional study that assigns participants to a tested intervention. Its 1,538 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% higher).
The record links to 0 conditions, and to 4 interventions - of which bicalutamide is the first listed.
NCT00936390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00936390 about?
NCT00936390 is a clinical study titled "Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation th...
What is the current status of trial NCT00936390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2009-09. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT00936390?
The interventions under investigation include: bicalutamide (DRUG), flutamide (DRUG), Dose-Escalated Radiation Therapy (RADIATION), LHRH agonist (antagonist) therapy (DRUG).
Who is sponsoring clinical trial NCT00936390?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00936390's enrollment target sits among peer trials
1,538 151st of 2000 higher than 1,849 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia